Want to join the conversation?
$BIIB said that the Committee of Medicinal Products for Human Use (CHMP) of the European Medicines Agency recommended the approval of its Tysabri product. The opinion of the CHMP is now referred to the European Commission for final decision on approval. Tysabri is a therapy for the treatment of patients with relapsing forms of multiple sclerosis.
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.